Safety and Efficacy of Conivaptan in Hyponatremic Patients With Symptomatic Acute Decompensated Heart Failure (ADHF)
Status:
Terminated
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and effectiveness of Conivaptan, a vasopressin
antagonist, in the treatment of hyponatremic subjects having symptomatic acute decompensated
heart failure (ADHF).